Gabapentin and Qsymia drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gabapentin and Qsymia. Common interactions include confusional state among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people who take Gabapentin and Qsymia have. It is created by eHealthMe based on reports of 57 people who take Gabapentin and Qsymia from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 09, 2023

57 people who take Gabapentin and Qsymia together, and have interactions are studied.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 273,741 Gabapentin users for its effectiveness, alternative drugs and more.

What is Qsymia?

Qsymia has active ingredients of phentermine hydrochloride; topiramate. It is often used in weight loss. eHealthMe is studying from 3,334 Qsymia users for its effectiveness, alternative drugs and more.

Number of Gabapentin and Qsymia reports submitted per year:

Common Gabapentin and Qsymia drug interactions by gender *:

female:

Confusional state
Diarrhoea
Drug ineffective
Gastrooesophageal reflux disease
Glycosylated haemoglobin decreased
Hip arthroplasty
Impaired gastric emptying
Kidney fibrosis
Limb discomfort
Mental impairment

male:

Dyspnoea
Abdominal pain
Bone density decreased
Bone pain
Chronic kidney disease
Depression
Drug ineffective
Drug resistance
Emotional distress
Fanconi syndrome acquired

Common Gabapentin and Qsymia drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Chronic kidney disease
Drug ineffective
Paraesthesia
Affective disorder
Anhedonia
Anxiety
Bone density decreased
Bone pain
Depression
Drug resistance

50-59:

Hypertension
Weight increased
Dry mouth
Hordeolum
Vision blurred
Arrhythmia
Arthritis
Balance disorder
Cardiomegaly
Cerebral disorder

60+:

Memory impairment
Decreased interest
Crying
Dizziness
Fatigue
Somnolence
Weight increased
Amnesia
Mental impairment
Stress

Common conditions people have *:

Weight Decreased: 23 people, 40.35%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 13 people, 22.81%
High Blood Pressure: 13 people, 22.81%
High Blood Cholesterol: 11 people, 19.30%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 9 people, 15.79%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 8 people, 14.04%
Pain: 8 people, 14.04%
Stress And Anxiety: 7 people, 12.28%
Depression: 6 people, 10.53%
Type 2 Diabetes: 5 people, 8.77%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and Qsymia?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Gabapentin (273,741 reports)
Qsymia (3,334 reports)